NCT00725452View on ClinicalTrials.gov

Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900)

CompletedOBSERVATIONAL
Enrollment

26

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Psoriasis
Interventions
BIOLOGICAL

Infliximab

Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.

Sponsors

Collaborators (1)

Centocor, Inc.
All Listed Sponsors
collaborator

Centocor, Inc.

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY